Pharmaceutical Statistics

Table of Contents

Pharmaceutical Statistics - Early View Articles



Statistical considerations in a delayed‐start design to demonstrate disease modification effect in neurodegenerative disorders

  • Author: Deli Wang, Weining Robieson, Jun Zhao, Catherine Wiener, Gary Koch
  • Pub Online: Jan 29, 2019
  • DOI: 10.1002/pst.1931 (p )


Design of experiments and the virtual PCR simulator: An online game for pharmaceutical scientists and biotechnologists

  • Author: Harold Fellermann, Ben Shirt‐Ediss, Jerzy Kozyra, Matt Linsley, Dennis Lendrem, John Isaacs, Thomas Howard
  • Pub Online: Feb 21, 2019
  • DOI: 10.1002/pst.1932 (p )


Estimation of drug effect in radiographic progression for rheumatoid arthritis and psoriatic arthritis

  • Author: Bin Dong, Jiandong Lu
  • Pub Online: Feb 26, 2019
  • DOI: 10.1002/pst.1936 (p )

Milestone prediction for time‐to‐event endpoint monitoring in clinical trials

  • Author: Fang‐Shu Ou, Martin Heller, Qian Shi
  • Pub Online: Feb 26, 2019
  • DOI: 10.1002/pst.1934 (p )

Statistical testing strategies for assessing treatment efficacy and marker accuracy in phase III trials

  • Author: Takahiro Nonaka, Masataka Igeta, Shigeyuki Matsui
  • Pub Online: Mar 05, 2019
  • DOI: 10.1002/pst.1937 (p )

Multivariate two‐sample permutation tests for trials with multiple time‐to‐event outcomes

  • Author: Inger Persson, Lukas Arnroth, Måns Thulin
  • Pub Online: Mar 26, 2019
  • DOI: 10.1002/pst.1938 (p )

Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned

  • Author: Fabiola La Gamba, Tom Jacobs, Helena Geys, Thomas Jaki, Jan Serroyen, Moreno Ursino, Alberto Russu, Christel Faes
  • Pub Online: Apr 01, 2019
  • DOI: 10.1002/pst.1941 (p )

From waterfall plots to spaghetti plots in early oncology clinical development

  • Author: Francois Mercier, Nicola Consalvo, Nicolas Frey, Alex Phipps, Benjamin Ribba
  • Pub Online: Apr 03, 2019
  • DOI: 10.1002/pst.1944 (p )

A generalized Bayesian nonlinear mixed‐effects regression model for zero‐inflated longitudinal count data in tuberculosis trials

  • Author: Divan Aristo Burger, Robert Schall, Rianne Jacobs, Ding‐Geng Chen
  • Pub Online: Apr 07, 2019
  • DOI: 10.1002/pst.1933 (p )

Assessing noninferiority: Evaluating efficacy of a new treatment without complete data

  • Author: Ping Gao, Katherine Odem‐Davis
  • Pub Online: Apr 12, 2019
  • DOI: 10.1002/pst.1946 (p )

Equilibrium, affinity, dissociation constants, IC5O: Facts and fantasies

  • Author: Jacques Barbet, Sandrine Huclier‐Markai
  • Pub Online: Apr 12, 2019
  • DOI: 10.1002/pst.1943 (p )

A flexible parametric survival model for fitting time to event data in clinical trials

  • Author: Jason J.Z. Liao, Guanghan Frank Liu
  • Pub Online: Apr 29, 2019
  • DOI: 10.1002/pst.1947 (p )

Choosing between the BP and BN sequential strategies

  • Author: Donna K. McClish, Amber R. Wilk, Christine M. Schubert
  • Pub Online: May 08, 2019
  • DOI: 10.1002/pst.1945 (p )

Controlling for confounding via propensity score methods can result in biased estimation of the conditional AUC: A simulation study

  • Author: Hadiza I. Galadima, Donna K. McClish
  • Pub Online: May 20, 2019
  • DOI: 10.1002/pst.1948 (p )


Page:   1 2 3 Next

Related Topics

Related Publications

Related Content

Site Footer


This website is provided by John Wiley & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ (Company No: 00641132, VAT No: 376766987)

Published features on are checked for statistical accuracy by a panel from the European Network for Business and Industrial Statistics (ENBIS)   to whom Wiley and express their gratitude. This panel are: Ron Kenett, David Steinberg, Shirley Coleman, Irena Ograjenšek, Fabrizio Ruggeri, Rainer Göb, Philippe Castagliola, Xavier Tort-Martorell, Bart De Ketelaere, Antonio Pievatolo, Martina Vandebroek, Lance Mitchell, Gilbert Saporta, Helmut Waldl and Stelios Psarakis.